The RBD mutations L452R, T478K, and E484Q were especially found in lineage B.1.617.2 and were described as the strains' hallmark alterations [28; 29]. The mutations L452R, T478K, E484Q, D614G, and P681R in the spike protein, including inside the receptor-binding domain, were also reported as a globally circulating lineage [30; 31]. Although found within the RBD and insensitive to several monoclonal antibodies (mAbs), the L452R, T478K, and E484Q alterations are of special significance [32; 33]. These mutations have shown an upsurge in viral transmissibility from 18.6% to 24%. While compared to the Wuhan-originated or wild-type SARS-CoV-2, the neutralizing ability towards B.1.617.2 was shown to be 5.8 times lower in recent research [34; 35]. Likewise, spike mutations in the N-terminal domain (NTD) of the lineage B.1.617.2 increase immune evasion capacity [36; 37]. Secondly, a shred of rising evidence has demonstrated that the NTD is a viable target for therapeutic and vaccination strategies [38; 39]. In addition, recent research revealed that numerous neutralizing antibodies adhered to the S1-NTD exclusively, preventing its communication with the host cells [40; 41]. [PERSON] et al. reported that the alteration N234Q was unusually resistant to nullifying antibodies; conversely, N165Q grew increasingly susceptible. Based on this scientific evidence and information, new drugs can be developed by interacting with the S1-NTD [42]. The continued spread of the highly transmissible SARS-CoV-2 delta strain underscores the necessity of getting vaccinated against COVID-19 [43; 44]. However, current research reported that with two doses of the Pfizer/BioNTech vaccination the real efficacy slightly lowered from 93.4% to 87.9% against B.1.1.7 and B.1.617.2, according to a negative case-control study carried out in England [45]. The AstraZeneca vaccine efficacy was substantially reduced from 66.1% to 59.8% against B.1.617.2 [46]. The emergence of viral variations that may evade the immunological response given by vaccinations has created a different problem [47]. As a result, discovering a treatment for SARS-CoV-2 infections is still necessary. The presented study suggests that repurposing and exploitingnaturally occurring chemicals employing in silico techniques might be promising treatments for COVID-19, achieved within a short timeframe and at a reasonable price [48, 49, 50, 51, 52, 53, 54, 55, 56]. Siddha and Ayurvedic medicine, which originated in Tamil Nadu, South India, are two of the oldest traditional remedies [57, 58, 59]. The government of India has recommended Kabasura kudineer choornam for combating a COVID-19 viral infection. Since the lungs are the primary organ of kapha, Kabasura kudineer choornam is a polyhedral Siddha composition that includes 15 herbs suggested to manage typical respiratory illnesses, such as colds, coughs, breathing difficulties, and the flu [60, 61, 62]. In silico investigations revealed that the Kabasura kudineer formulation had anti-inflammatory, antipyretic, and antibacterial properties; as well, it poses a better ability to bind to the SARS-CoV-2 spike protein [63, 64]. Likewise, _Houttuynia cordata_ (_H. cordata_) played a vital role in herbal therapy for the SARS outbreak in Southern China in 2003 [65]. Furthermore, it acts effectively against chikungunya, human noroviruses, human herpes viruses, the dengue virus, influenza, the pseudorabies virus, and murine coronaviruses [66, 67]. [PERSON] et al. discovered _H. Cordata_ phytocompounds to be a potential inhibitor for Mpro and PLpro, thereby preventing the replication of SARS-CoV-2 [68]. Similarly, the dried flower bud _Syzygium aromaticum_ (_S. aromaticum_), a plant indicated by the English name \"clove,\" acts effectively against COVID-19 [69]. Spices such as cloves are used in three forms: whole dried buds, powdered cloves, or extracted as an essential oil.